Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

Basal cell carcinoma, for example, has a five-year survival rate of 100%. Pancreatic ductal adenocarcinoma, however, has a five-year survival rate of just 4%. Carcinoma is curable if detected early.

This was repeated for an American support group for nevoid basal cell carcinoma syndrome ... gray-white, 3 to 4 cm in diameter, and may, upon occasion, exhibit central calcification.

A phase II trial reports success with an innovative immunotherapy for difficult-to-resect basal cell carcinoma, reducing ...

In this investigator-initiated trial, Choueiri and Braun treated nine patients with stage III or IV clear cell renal cell carcinoma with a personalized cancer vaccine after surgery. Five patients ...